Navigation Links
PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
Date:4/21/2010

l prediction to identify other tumors that are potential candidates for new preclinical and clinical trials with the compound. Phase II clinical trials are currently under way with Yondelis(R) in breast, lung and prostate cancers and pediatric tumors.

Three other trials presented at the AACR meeting provided new data on Irvalec(R), a novel marine-based synthetic depsipeptide currently in Phase II trials for lung cancer.

The first trial is evaluating the modulation of initial cytotoxic effects of Irvalec(R) using zinc and DIDS in lung cancer cells. The results suggest that plasma membrane damage caused by Irvalec(R) generates a rapid onset of hydroelectrolyte imbalance, causing severe alterations that lead to cell death by necrosis.

A second trial sheds light on the molecular mechanism associated with sensitivity and resistance to Irvalec(R). Conclusions show that primary and acquired resistance to Irvalec(R) may be associated with the expression of ErbB receptors and epithelial mesenchymaltransition markers.

A third trial shows that overexpression of ErbB2 and ErbB3 receptors does not affect sensitivity to Irvalec(R), although the receptors do suffer some changes as a result of alterations in the cell membrane produced by the compound.

Another trial suggests that PDGFRA could be a useful predictive biomarker of response to Zalypsis(R), a novel chemical entity related to the marine natural compounds jorumycin and the renieramycin family, obtained from mollusks and sponges. Zalypsis(R) is currently in Phase II trials for endometrial and cervical cancer.

About PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis(R) is '/>"/>

SOURCE PharmaMar
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
3. Limbs for Life Foundation Presents the Roaring 20s at 9th Annual Benefit Gala and Auction
4. The Womens Heart Foundation Presents the Womens Heart Advocate Award for Medicine and Science to Multifunction CardioGram(TM) Inventor Dr. Joseph T. Shen
5. Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
6. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
7. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
8. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
9. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
10. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
11. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 This study provides ... imaging informatics solutions including nuclear imaging informatics, PET ... The study assesses the size of the market ... 2013, and projects future growth based on the ... dynamics taking place in the broader markets for ...
(Date:9/30/2014)... 30, 2014  Decision Resources Group finds that the ... , China , India , ... strong rate through 2023. Dental implant procedure volumes will grow as ... rises. Other key findings from Decision Resources Group,s coverage ... , Dental implant penetration: Penetration of dental implants ...
(Date:9/30/2014)... 2014 A study using a relatively new ... look at the composition of carotid artery disease and ... treat the disease, a leading cause of stroke. ... between September 2010 and May 2012, was featured in ... the American College of Cardiology (JACC) Cardiovascular Interventions. ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... 20, 2010 / PRNewswire-USNewswire/ -- As the season of ... to consider giving a simple gift that can make a ... initiative of the AMA Foundation that works with leading humanitarian ... in areas of need. Anyone can donate a new or ...
... 20, 2010 Each year, the Food and Drug ... wide variety of conditions and help consumers save money. ... for generic medications, go to http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm236544.htm . ... Consumer Updates at: https://service.govdelivery.com/service/subscribe.html?code=USFDA_9 . ...
Cached Medicine Technology:'Tis the Season to Give a Gift that Can Make a World of Difference 2
(Date:9/30/2014)... Centers (FQHCs) granted new patient appointments to Medicaid ... other primary care practices (non-FQHCs), in addition to ... a new 10-state University of Pennsylvania study published ... Using data from a previous "secret shopper" study ... that FQHCs community health clinics that receive ...
(Date:9/30/2014)... 30, 2014(BRONX, NY)Medications are the leading cause of allergy-related ... of death certificates from 1999 to 2010, conducted by ... Albert Einstein College of Medicine of Yeshiva University ... Journal of Allergy and Clinical Immunology , also found ... particularly high among older people and African-Americans and that ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... certified nutrition specialist and best-selling author Mike Geary that is ... totally transform their body into a fat-burning machine in less ... prompting an investigative review. , “In our culture that ... can be hard to decipher what is really fact and ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
Breaking Medicine News(10 mins):Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2
... has mutated since 2002 to become more dangerous //and increases ... Asian strain H5N1 influenza virus has changed its characters since ... the virus multiplies in the ducks without infecting them but ... is a natural host for H5N1 influenza virus, these ducks ...
... on findings of a recent study researchers from Sweden ... stent is associated with coronary vasoconstriction in areas adjacent ... bare metal stents. ,Sirolimus-eluting stents are widely ... long-term clinical and angiographic outcome, however, recent concerns have ...
... often come to this side of the content //to get ... own countries. ,More and more Globetrotters are making a ... monsoons. Why you may ask? Well it’s believed strongly that ... in the rainy months of June, July and August. ...
... study by investigators from Sahlgrenska University Hospital in Gothenburg, ... outcomes of the health condition called drug-induced liver disease. ... Although stops when the medication is withdrawn, some effects ... can be fatal. An observation made by Dr. Hyman ...
... jail was detected as HIV positive //and admitted to a government ... Jail here, was diagnosed as HIV positive at the Patna Medical ... in a Bihar prison., ,The woman from a village in ... murder charge, has "almost" full blown AIDS, said M.P. Singh, who ...
... farm animals and spread in humans// by inhaling spores from infected ... taken. Now a report of Anthrax among the farm animals of ... disease among the health officials. ,Kerala has also imposed ban ... – a market town on the border of Kerala and Tamil ...
Cached Medicine News:Health News:Influenza Avian Flu strain has become more contagious and dangerous. , 2Health News:Influenza Avian Flu strain has become more contagious and dangerous. , 3Health News:Analyzing The Side Effects Of Sirolimus Stents 2Health News:Ayurvedic Therapies Cashing In On Medical Tourism 2Health News:Anthrax Scare In Tamil Nadu State of India 2
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... introduces the Tag-It™ Cystic Fibrosis Kit, the ... genotyping. With validated performance criteria, this highly ... superior mutation coverage for carrier screening in ... in newborns. ,The Tag-It™ Cystic Fibrosis ...
Medicine Products: